智通财经APP获悉，复宏汉霖(02696)盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53 万港元。 消息面上，据药研网报道，2026年ASCO GI会议即将在(2026年1月8日-2026年1月10日)召开，官方公布 了本次胃肠道肿瘤研讨会(ASCO GI)摘要内容。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗 复发/转移性食管鳞状细胞癌(ESCC)中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检 查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本 项Ⅱ期研究旨在评估HLX43用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。 ...

消息面上，据药研网报道，2026年ASCO GI会议即将在(2026年1月8日-2026年1月10日)召开，官方公布 了本次胃肠道肿瘤研讨会(ASCO GI)摘要内容。其中，复宏汉霖首次公布其PD-L1ADC药物HLX43治疗 复发/转移性食管鳞状细胞癌(ESCC)中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检 查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本 项Ⅱ期研究旨在评估HLX43用于经治复发/转移性食管鳞状细胞癌患者的疗效与安全性。 复宏汉霖(02696)盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53万港元。 ...

1)HLX43是全球潜在BICPD-L1ADC，肺癌、胃癌、胸腺癌等多适应症临床在研。继2025年9月WCLC大 会更新1期数据后(共计56例)，2025年11月2日公司公布了HLX43治疗NSCLC的关键更新数据，首次合并 了国际多中心II期临床结果，总人群疗效显著：鳞状NSCLC患者(2mg/kg，n=33)ORR为33.3%，非鳞状 NSCLC患者(2.5mg/kg，n=35)ORR为48.6%。同时，HLX43不依赖生物标志物筛选：PD-L1阴性(TPS＜ 1%，n=43)患者ORR为39.5%，提示疗效不受PD-L1表达限制，有望覆盖更广泛群体。此外，HLX43安 全性良好：血小板计数减少仅1.7%，血液学毒性较低。9.8%患者报告了irAE，2.9%患者出现免疫相关 性肺病，但观察到显著治疗获益：40%的cORR及100%的肿瘤缩小率，提示其疗效经由小分子毒素以及 免疫机制共同介导。同时，2025ESMOAsia披露：HLX43在晚期宫颈癌II期临床研究中展现了优异的初 步临床疗效，ORR为37.9%，DCR为72.4%，且安全性可控。2)HLX22：与曲妥珠单抗联用更优效、安 全，HLX22联合 ...

Core Viewpoint - Fuhong Hanlin (复宏汉霖) is positioned as a leading player in the biosimilar drug market in China, focusing on hematological malignancies, solid tumors, and autoimmune diseases, with a strong emphasis on international collaboration and product commercialization [1][2] Group 1: Business Performance - In 2023, the company achieved profitability with projected revenue of 5.724 billion yuan in 2024, representing a 6% year-on-year growth, and a net profit of 815 million yuan, reflecting a 50% increase compared to the previous year [2] - The company is expected to enter a high-growth phase in overseas business by 2025, with overseas product profits projected to grow over 200% in the first half of 2025 [2] Group 2: Product Pipeline and R&D - HLX43, a potential BICPD-L1ADC, is under clinical development for multiple indications including lung cancer and gastric cancer, showing significant efficacy in clinical trials with an overall response rate (ORR) of 33.3% for squamous NSCLC and 48.6% for non-squamous NSCLC [3] - HLX22, in combination with trastuzumab, has shown improved efficacy and safety in treating HER2-positive gastric/gastroesophageal junction cancer, with ongoing global Phase III trials [3] - The company is also advancing the development of Surulitinib, which aims to replace postoperative chemotherapy in gastric cancer with immunotherapy, having met primary clinical endpoints [3] Group 3: Market Strategy and Valuation - The company has established a global presence with its biosimilar products, which are key drivers of revenue growth, and is considering implementing full circulation of H-shares to enhance liquidity [4] - The projected net profits for 2025-2027 are estimated at 823 million, 744 million, and 1.129 billion yuan respectively, with corresponding price-to-earnings ratios of 39, 43, and 28, suggesting a total market valuation between 52.1 billion and 67.9 billion yuan [4]

（n=10）、2.5 mg/kg（n=10）和3 mg/kg（n=10）的HLX43 治疗。其中超过80%的患者CPS≥1。 患者既往接受肿瘤治疗的中位线数为2.0（范围1–4 线）。全部患者接受过铂类药物化疗，60%的患者接 受过靶向治疗，约50%患者接受过免疫治疗，中位随访时间为3.5 个月。 有效性方面，整体ORR 为41.4%，DCR 为82.8%。3 mg/kg 剂量组的ORR和DCR 为70.0%和100%，患者 中位PFS 尚未达到。 机构：天风证券 研究员：杨松/刘一伯 事件 2025 年12 月5 日，复宏汉霖在ESMO Asia 披露其PD-L1 ADC HLX43 用于复发/转移性宫颈癌的II 期临 床研究数据。继非小细胞肺癌、胸腺癌之后，再度印证了HLX43 在实体瘤领域的广谱治疗潜力。横向 对比，HLX43 的有效性领先同适应症已上市/在研药物，安全性良好，再次展现出色的商业化前景。 疗效优势明显，安全性良好可控 本次数据基于一项开放、随机、多中心的II 期临床研究，研究共纳入30例经组织学确诊为复发/晚期宫 颈癌（CC）且既往接受过标准一线治疗失败、不耐受或禁忌的患者。随机分配接受 ...

Market Overview - The pharmaceutical and biotechnology index increased by 2.19%, outperforming the Shanghai Composite Index by 2.65 percentage points, ending a nearly two-month period of sluggish performance [4] - The innovative drug index (BK1106) rose by 4.93%, while the Hang Seng Healthcare Index (HSCICH) surged by 7.18%, and the Hong Kong innovative drug ETF (513120) increased by 5.90% [4][5] Investment Insights - The recent rebound in the pharmaceutical sector indicates a recovery in market sentiment, with a notable increase in risk appetite [5] - Investors are advised to focus on two main themes: capitalizing on valuation recovery opportunities in innovative drugs and medical devices, and being cautious of concept stocks lacking fundamental support [5] - Companies with strong global innovation capabilities and progress in international markets are highlighted as key investment targets [5] Company Developments - Fuxiang Pharmaceutical, primarily engaged in the development and sales of anti-infection drug raw materials, has seen its stock performance closely tied to the rising prices of lithium battery electrolyte additives, rather than traditional pharmaceutical concepts [5] - The company is expanding into synthetic biology and microbial protein businesses [5] Clinical Trials and Approvals - A total of 94 new clinical trial registrations were disclosed, with 37 in Phase II or above [9] - Notable clinical trials include the evaluation of HLX43 for late-stage pancreatic cancer, which has commenced its Phase II study [15] - The approval of innovative drugs includes the launch of Vepaglutide by Paig Biological, aimed at improving blood sugar control in adults with type 2 diabetes [13][14] IPO and M&A Activity - Jiahe Biopharma is pursuing a reverse merger with Yiteng Pharmaceutical, marking the first reverse acquisition case under the Hong Kong 18A listing rules for biotech companies [7][8] - Jiahe Biopharma reported a revenue of 32.245 million yuan, a year-on-year increase of 122.84%, despite a loss of 54.373 million yuan during the same period [7]

Market Overview - The pharmaceutical and biotechnology index increased by 2.19%, outperforming the Shanghai Composite Index by 2.65 percentage points, ending a two-month period of sluggish performance [3] - The innovative drug index (BK1106) rose by 4.93%, while the Hang Seng Healthcare Index (HSCICH) saw a 7.18% increase [3] - The Hong Kong innovative drug ETF (513120) experienced a 5.90% rise [3] Company Highlights - Fuxiang Pharmaceutical, primarily engaged in the research, production, and sales of anti-infection drug raw materials and intermediates, saw its stock price surge by 64.46% [4] - Beibete-U, an innovative drug company that recently listed on the STAR Market, faced a significant decline, attributed to its slow clinical trial progress and lack of immediate product support [5] - Jiayou Bio's merger proposal with Yiteng Pharmaceutical Group marks the first reverse acquisition case under the Hong Kong 18A listing rules for biotech companies [6][7] Clinical Trials - A total of 94 new clinical trial registrations were disclosed, with 37 being in Phase II or above [9] - Notable trials include HLX43, an ADC targeting PD-L1 for advanced pancreatic cancer, which has commenced its Phase II clinical study [18] Product Approvals - Three innovative drugs received approval, including Vepaglutide for type 2 diabetes, marking a significant milestone for Paige Bio [13][15] - The competitive landscape for GLP-1 drugs is intensifying, with major players like Novo Nordisk and Eli Lilly holding a combined market share of 84% [15][16]

Core Viewpoint - Citibank hosted its 2025 China Summit and reaffirmed its "Buy" rating for Fosun International (00656.HK), raising the target price to HKD 6.5, highlighting the company's strategic focus on core businesses and global expansion [1] Group 1: Strategic Focus and Financial Health - Fosun International is committed to a "streamlining and focusing" strategy, optimizing its financial structure, and demonstrating a strong determination in deleveraging and disposing of non-core assets [1] - Multiple domestic and international brokerages, including Citibank and UBS, maintain a "Buy" or "Overweight" rating for Fosun, with target prices ranging from HKD 6.5 to HKD 7.5, reflecting confidence in the company's business resilience and innovation potential [1] Group 2: Health Sector Innovations - Fosun's health sector is driven by innovation, with several breakthrough drugs, including the first PD-1 monoclonal antibody approved for small cell lung cancer treatment, now available in nearly 40 countries [2] - Another innovative drug, HLX43, is undergoing clinical trials in multiple countries and has the potential to become a highly effective and safe broad-spectrum anti-cancer drug [2] Group 3: Tourism and Consumer Sectors - During the 2025 National Day and Mid-Autumn Festival, Fosun's tourism sector saw significant visitor numbers and revenue growth, with Club Med resorts reporting a 36% increase in total revenue year-on-year [3] - The consumer sector is adjusting its strategy, with expectations for recovery in the jewelry segment, supported by improving performance and market conditions [3] Group 4: Asset Management and Fintech Innovations - Fosun is innovating in asset management and fintech, with its subsidiary, Xinglu Technology, becoming a leading player in Hong Kong's fintech market, focusing on AI-driven wealth technology [4] - The company is advancing into the virtual asset market and has launched the FinRWA Platform, providing compliant and efficient Web3 access services [4] - Brokerages view Fosun's core industries as stable, with a focus on leveraging strengths and potential, enhancing global presence, and increasing technological innovation [4]

Group 1: Company Overview - Citibank hosted its 2025 China Summit and reaffirmed a "Buy" rating for Fosun International, raising the target price to HKD 6.5, reflecting confidence in the company's strategic focus on core businesses and global expansion [1] - Multiple domestic and international brokerages maintain a "Buy" or "Overweight" rating for Fosun International, with target prices ranging from HKD 6.5 to 7.5, indicating strong market sentiment towards the company's resilience and innovation potential [1] Group 2: Health Sector - Fosun's health segment is driven by innovation, with several breakthrough drugs, including the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer, now available in nearly 40 countries [2] - The insurance segment, exemplified by Fidelidade, is projected to achieve steady growth with a 12.7% year-on-year increase in insurance revenue and a net profit of EUR 253 million, maintaining a strong market position [2] Group 3: Tourism and Consumption - During the 2025 National Day and Mid-Autumn Festival, Fosun's tourism sector saw significant visitor numbers, with Club Med resorts reporting a 36% year-on-year increase in total revenue and a 213% surge in inbound tourists [3] - The consumption sector is undergoing strategic adjustments, with expectations for recovery in core businesses, particularly in jewelry, as market conditions improve and global expansion deepens [3] Group 4: Asset Management and Fintech - Fosun is innovating in asset management and fintech, with its subsidiary, Xinglu Technology, emerging as a leading player in Hong Kong's fintech market, focusing on AI-driven wealth technology [4] - The company is advancing into the virtual asset market with the FinRWA Platform, providing compliant Web3 access services and launching several innovative projects, including the first tokenized fund in Hong Kong [4]

Group 1: Core Business Strategy - Citibank hosted its 2025 China Summit and reiterated a "Buy" rating for Fosun International, raising the target price to HKD 6.5, highlighting the company's focus on core business and global expansion [1] - Fosun is committed to optimizing its financial structure, with a strong determination to reduce leverage and dispose of non-core assets, which is expected to enhance financial stability and focus on core operations [1][2] - Multiple domestic and international brokerages maintain a "Buy" or "Increase" rating for Fosun International, with target prices ranging from HKD 6.5 to 7.5, reflecting confidence in the company's business resilience and innovation [1] Group 2: Health Sector Innovations - Fosun's health sector is driven by innovation, with several breakthrough drugs, including the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer, now available in nearly 40 countries [2] - Another innovative drug, HLX43, is undergoing clinical research in various countries and has the potential to become a highly effective and safe broad-spectrum anti-cancer drug [2] Group 3: Tourism and Consumer Sectors - During the 2025 National Day and Mid-Autumn Festival, the Taicang Alps International Resort received over 50,000 visitors, and Club Med resorts saw a nearly 10% increase in average daily room rates [3] - The consumer sector is adjusting strategies, with expectations for growth in the jewelry segment, as indicated by the resilience of Fosun's consumer business [3] Group 4: Asset Management and Fintech Innovations - Fosun is innovating in asset management and fintech, with its subsidiary, Xinglu Technology, becoming a leading fintech company in Hong Kong, focusing on AI-driven wealth technology [4] - Xinglu Technology has launched the FinRWA Platform, providing compliant and efficient Web3 access services, and has been recognized as a key enterprise by the Hong Kong government [4] - Brokerages express optimism about Fosun's core industries and its focus on technological innovation, which is expected to enhance its long-term growth potential [4]